CD274 and head and neck squamous cell carcinoma: More recently IRX-2, a natural cytokine mixture was tested in neoadjuvant setting as monotherapy in stage II-IV OSCC [18] or as combinational therapy with anti-PD-L1 (durvalumab) [19] for the treatment of metastatic or recurrent SCCHN, with limited success.